A phase 2 randomized, double-blind, placebo-controlled, parallel group, dose-ranging study to evaluate the phase-shifting effects of repeated daily dosing of TAK-375 [ramelteon] in healthy subjects.
Phase of Trial: Phase II
Latest Information Update: 09 Jun 2013
At a glance
- Drugs Ramelteon (Primary)
- Indications Insomnia
- Focus Pharmacodynamics
- Sponsors Takeda
- 31 Aug 2018 Biomarkers information updated
- 28 May 2008 New trial record.